Suppr超能文献

对荷瘤大鼠组织高分解代谢的药理学干预。

Pharmacological interference with tissue hypercatabolism in tumour-bearing rats.

作者信息

Tessitore L, Costelli P, Baccino F M

机构信息

Dipartimento de Medicina ed Oncologia Sperimentale, Universitá di Torino, Italy.

出版信息

Biochem J. 1994 Apr 1;299 ( Pt 1)(Pt 1):71-8. doi: 10.1042/bj2990071.

Abstract

Marked loss of body weight and profound waste of both skeletal muscle and white adipose tissue occur in rats into which the ascites hepatoma Yoshida AH-130 has been transplanted, associated with marked perturbations in the hormonal homoeostasis and the presence of circulating tumour necrosis factor and high plasma levels of prostaglandin E2 [Tessitore, Costelli and Baccino (1993) Br. J. Cancer 67, 15-23]. On the basis of previous findings, the present study examined whether the development of cachexia in this model system could be significantly affected by adrenalectomy or by pharmacological treatments that may interfere with proximal or distal mediators of tissue hypercatabolism. In no instance was tumour growth modified. Medroxyprogesterone acetate, an anabolic-hormone-like drug, was completely ineffective. In adrenalectomized animals, although changes such as the elevation of plasma triacylglycerols and corticosterone were corrected, the general course of cachexia was not modified. A partial prevention of muscle waste was observed with acetylsalicylic acid, a non-steroidal anti-inflammatory drug, or with leupeptin, a proteinase inhibitor. Insulin afforded the most significant preservation of muscle protein and adipose-tissue mass, which were maintained close to control values even 10 days after transplantation. The effects of insulin on gastrocnemius muscle and liver protein content were exerted by slowing down protein turnover, mainly enhancing synthesis. Consistently, the total free amino acid concentration in the gastrocnemius of insulin-treated rats 10 days after tumour transplantation was close to that of controls. Although treatment with insulin decreased plasma corticosterone to normal values, it did not modify the circulating level of tumour necrosis factor. On the whole these data show that it seems possible to prevent, at least in part, the tissue waste that characterizes cancer cachexia by purely pharmacological means.

摘要

将吉田腹水肝癌AH - 130移植到大鼠体内后,大鼠出现明显体重减轻,骨骼肌和白色脂肪组织严重消耗,同时伴有激素稳态的显著紊乱,以及循环肿瘤坏死因子的出现和血浆中前列腺素E2水平升高[泰西托雷、科斯特利和巴奇诺(1993年)《英国癌症杂志》67卷,第15 - 23页]。基于先前的研究结果,本研究探讨了在该模型系统中恶病质的发展是否会受到肾上腺切除术或可能干扰组织分解代谢近端或远端介质的药物治疗的显著影响。在任何情况下肿瘤生长均未改变。合成代谢激素样药物醋酸甲羟孕酮完全无效。在肾上腺切除的动物中,尽管血浆三酰甘油和皮质酮升高之类的变化得到了纠正,但恶病质的总体进程并未改变。非甾体抗炎药乙酰水杨酸或蛋白酶抑制剂亮肽素可部分预防肌肉消耗。胰岛素对肌肉蛋白和脂肪组织量的保存作用最为显著,甚至在移植后10天,这些指标仍维持在接近对照值的水平。胰岛素对腓肠肌和肝脏蛋白含量的影响是通过减缓蛋白周转,主要是增强合成来实现的。一致地,肿瘤移植10天后,胰岛素处理的大鼠腓肠肌中总游离氨基酸浓度接近对照组。尽管胰岛素治疗使血浆皮质酮降至正常水平,但它并未改变肿瘤坏死因子的循环水平。总体而言,这些数据表明,至少在一定程度上,似乎有可能通过单纯的药物手段预防癌症恶病质所特有的组织消耗。

相似文献

1
Pharmacological interference with tissue hypercatabolism in tumour-bearing rats.
Biochem J. 1994 Apr 1;299 ( Pt 1)(Pt 1):71-8. doi: 10.1042/bj2990071.
2
Humoral mediation for cachexia in tumour-bearing rats.
Br J Cancer. 1993 Jan;67(1):15-23. doi: 10.1038/bjc.1993.4.
7
Lack of effect of eicosapentaenoic acid in preventing cancer cachexia and inhibiting tumor growth.
Cancer Lett. 1995 Oct 20;97(1):25-32. doi: 10.1016/0304-3835(95)03944-r.
8
Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats.
Br J Cancer. 2000 Aug;83(4):526-31. doi: 10.1054/bjoc.2000.1299.
9
Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals.
Arch Biochem Biophys. 1993 Oct;306(1):52-8. doi: 10.1006/abbi.1993.1479.

引用本文的文献

1
Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies.
J Cachexia Sarcopenia Muscle. 2023 Jun;14(3):1150-1167. doi: 10.1002/jcsm.13073. Epub 2023 Mar 2.
2
Apelin Resistance Contributes to Muscle Loss during Cancer Cachexia in Mice.
Cancers (Basel). 2022 Apr 2;14(7):1814. doi: 10.3390/cancers14071814.
3
Hypothalamic-pituitary-adrenal axis activation and glucocorticoid-responsive gene expression in skeletal muscle and liver of Apc mice.
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1686-1703. doi: 10.1002/jcsm.12939. Epub 2022 Mar 11.
4
Phenotypic features of cancer cachexia-related loss of skeletal muscle mass and function: lessons from human and animal studies.
J Cachexia Sarcopenia Muscle. 2021 Apr;12(2):252-273. doi: 10.1002/jcsm.12678. Epub 2021 Mar 30.
5
Muscle alterations in the development and progression of cancer-induced muscle atrophy: a review.
J Appl Physiol (1985). 2020 Jan 1;128(1):25-41. doi: 10.1152/japplphysiol.00622.2019. Epub 2019 Nov 14.
6
Interference with Ca-Dependent Proteolysis Does Not Alter the Course of Muscle Wasting in Experimental Cancer Cachexia.
Front Physiol. 2017 Apr 19;8:213. doi: 10.3389/fphys.2017.00213. eCollection 2017.
8
The regulation of muscle mass by endogenous glucocorticoids.
Front Physiol. 2015 Feb 3;6:12. doi: 10.3389/fphys.2015.00012. eCollection 2015.
9
Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle.
FASEB J. 2013 Sep;27(9):3572-82. doi: 10.1096/fj.13-230375. Epub 2013 Jun 3.
10
Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass.
J Cachexia Sarcopenia Muscle. 2012 Jun;3(2):77-94. doi: 10.1007/s13539-011-0052-4. Epub 2012 Jan 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验